The published tesamorelin results come from CT scans, not testimonials. Over 26 weeks visceral fat fell about 15% and IGF-1 roughly doubled, but the visceral fat returned once the drug was stopped.
Tesamorelin results come from large randomized controlled trials, not testimonials. Over 26 weeks, visceral fat fell about 15% and IGF-1 roughly doubled in adults with HIV-associated lipodystrophy [1][2]. The changes were measured by CT imaging rather than by the scale, and they reversed once the drug was stopped [3].
- Visceral fat fell 15.2% versus a 5.0% rise on placebo over 26 weeks [1]
- A pooled analysis of 806 patients found a 15.4% treatment effect at 26 weeks and 17.5% at 52 weeks [2]
- IGF-1 rose 81.0% versus a 5.0% decrease on placebo [1]
- Results were measured by CT scan, not weight; total body weight changed little [1]
- Visceral fat reaccumulated after the drug was discontinued [3]
What the Trials Actually Measured
The tesamorelin endpoint was visceral adipose tissue, quantified by CT scan at the L4-L5 vertebral level, plus IGF-1 as the biochemical marker of GH-axis response. This matters for interpreting results, because visceral fat sits deep around the organs and does not track with scale weight or waist appearance in a simple way. A meaningful visceral fat reduction can occur with little change in total body weight. Every result below comes from that HIV-lipodystrophy population, the only one in which the drug is approved and was studied [5].
The Primary Result: Visceral Fat
In the first large trial of 412 patients, visceral adipose tissue fell 15.2% with tesamorelin over 26 weeks, against a 5.0% increase on placebo [1]. A pooled analysis of two phase 3 trials covering 806 patients found a 15.4% treatment effect at 26 weeks that extended to 17.5% at 52 weeks [2]. A separate 404-patient trial reported a 10.9% reduction at 6 months [3].
| Trial | Population | Visceral fat change | Timeframe |
|---|---|---|---|
| Falutz 2007 (n=412) | HIV lipodystrophy | 15.2% reduction vs 5.0% rise on placebo [1] | 26 weeks |
| Pooled phase 3 (n=806) | HIV lipodystrophy | 15.4% effect, then 17.5% [2] | 26 then 52 weeks |
| Falutz 2010 (n=404) | HIV lipodystrophy | 10.9% reduction [3] | 6 months |
The IGF-1 Response
IGF-1 is the marker that confirms the GH axis responded, and tesamorelin moved it substantially. In the 412-patient trial, IGF-1 rose 81.0% on tesamorelin versus a 5.0% decrease on placebo [1]. That degree of elevation is expected from a stabilized GHRH analog dosed daily, and it is why baseline and follow-up IGF-1 testing is the honest way to confirm response rather than relying on how a patient looks or feels.
What Did Not Change
Tesamorelin is selective for visceral fat, so the outcomes people expect from a fat-loss drug did not all appear. Subcutaneous fat and total body weight showed little change, because the effect is concentrated on the deep abdominal compartment [4]. The result is a change in fat distribution more than a change on the scale.
Visceral fat reaccumulated after tesamorelin was stopped [3]. The drug suppresses a process rather than permanently resetting it, so results depend on continued use. Anyone planning a fixed-length course should expect gradual reversal afterward.
Timeline: When Results Appear
IGF-1 rises first, within the first weeks of daily dosing, and it is the earliest confirmation that the axis is engaged [6]. Visceral fat change develops over months, with the primary trial endpoints measured at 26 weeks and extended data at 52 weeks [1][2]. There is no meaningful before-and-after at 2 to 4 weeks. The fat result is a multi-month outcome.
| Timeframe | What changes |
|---|---|
| First 2 to 4 weeks | IGF-1 begins to rise; no visible fat change yet [6] |
| 26 weeks | Primary visceral fat endpoint, roughly 15% reduction [1][2] |
| 52 weeks | Effect extends to about 17.5% in pooled data [2] |
| After stopping | Visceral fat gradually reaccumulates [3] |
Why Before-and-After Photos Mislead Here
Photographs cannot show the result tesamorelin produces. Visceral fat sits beneath the abdominal wall, so a CT scan detects it and a camera does not. The trial results are documented as imaging and lab changes precisely because the visible change is modest relative to the internal one. Treat any dramatic tesamorelin before-and-after image with skepticism, and treat testimonials without lab values as perception rather than data.
The only honest way to judge a GHRH protocol is a baseline IGF-1 and a 90-day retest, the same markers the tesamorelin trials used. SystemLabs includes baseline IGF-1 testing before prescribing compounded sermorelin, so your result is measured rather than assumed.
What This Means if You Are Considering Sermorelin
The tesamorelin data sets a realistic expectation for any GHRH therapy: the changes are gradual, measured in labs and imaging, and dependent on continued use. Sermorelin acts on the same receptor with a thinner adult evidence base, where a controlled trial found IGF-1 elevation within 2 weeks and increased lean mass in men over 16 weeks, but no significant fat mass change in that short window [6]. The lesson is the same. Judge a GHRH protocol by IGF-1 movement over months, not by early photos.
Frequently Asked Questions
What results does tesamorelin produce?
In phase 3 trials, tesamorelin reduced visceral fat by about 15% over 26 weeks and raised IGF-1 by roughly 80%, measured against placebo [1]. Pooled data extended the visceral fat effect to 17.5% at 52 weeks [2]. Total body weight and subcutaneous fat changed little, because the effect is specific to deep abdominal fat.
How long does tesamorelin take to work?
IGF-1 begins rising within the first few weeks of daily dosing, but the visceral fat result is a multi-month outcome. The trial endpoints were measured at 26 weeks, with extended data at 52 weeks [1][2]. There is no meaningful visible change at 2 to 4 weeks.
Are tesamorelin before-and-after photos real?
Be skeptical. Tesamorelin reduces visceral fat, which sits beneath the abdominal wall and is measured by CT scan, not visible in a photograph [4]. The trials documented imaging and lab changes rather than dramatic external transformations. Photos without baseline and follow-up IGF-1 values are perception, not evidence.
Do tesamorelin results last after stopping?
No. Visceral fat reaccumulated after the drug was discontinued in the trials [3]. Tesamorelin suppresses visceral fat accumulation rather than permanently resetting it, so the effect depends on continued use. A fixed-length course should be expected to reverse gradually once stopped.
Does tesamorelin help you lose weight on the scale?
Not primarily. The drug is selective for visceral fat, and total body weight changed little in the trials [1]. It changes fat distribution more than scale weight. If the goal is scale weight loss, the GH axis is the wrong lever, and GLP-1 medication or lifestyle change has stronger direct evidence.
References
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes, 2010. PMID: 20101189. https://pubmed.ncbi.nlm.nih.gov/20101189/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2010. Initial U.S. Approval: 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
